Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: lactose monohydrate; titanium dioxide; purified water; quinoline yellow; gelatin; sodium lauryl sulfate; brilliant scarlet 4r - treatment of primary dysmenorrhoea and primary menorrhagia.,short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: lactose monohydrate; titanium dioxide; purified water; quinoline yellow; gelatin; sodium lauryl sulfate; brilliant scarlet 4r - treatment of primary dysmenorrhoea and primary menorrhagia.,short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

United States - English - NLM (National Library of Medicine)

micro labs limited - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see   warnings; gastrointestinal bleeding, ulceration, and perforation ). mefenamic acid is indicated: - for relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product ( see   warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). mefenamic acid is indicated: - for relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings; anaphylactic reaction, exacerbation of asth

United States - English - NLM (National Library of Medicine)

prasco laboratories - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ;   g astrointestinal  bleeding, ulceration, and perforation ). mefenamic acid is indicated: - for relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid is contraindicated in the following patients. - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (see warnings ;  anaphylactic reactions , serious skin reactions ). - history of asthma, urticarial, or other allergic-type reactions after taking aspirin or other nsaids.  severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings;    anaphylactic reaction,

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals,llc - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid and  other treatment options before deciding to use mefenamic acid. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see warnings). mefenamic acid is indicated: - for relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid is contraindicated in patients with known hypersensitivity to mefenamic acid. mefenamic acid should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings - anaphylactoid reactions, and precautions - preexisting asthma). mefenamic acid is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid capsules and other treatment options before deciding to use mefenamic acid capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation). mefenamic acid capsules are indicated: - for relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid capsules are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions). - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (seewarnings; anaphylactic reaction, exacerbation of asthma related to aspirin sensitivity). - in the setting of coronary artery bypass graft (cabg) surgery (see warnings; cardiovascular thrombotic events).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - mefenamic acid - oral capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - mefenamic acid - oral capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - mefenamic acid - oral capsule - 250mg